EXAMINING THE SLADE / TYRING CONTRIBUTIONS TO THE PROBLEM

 

 

In the early days of research conducted on the single and only active agent in Aldara, imiquimod, 3M relied exclusively upon researchers with career histories in the fields of immunology and molecular/micro biology to conduct their clinical trials.

 

If you are 3M and you really want to gain as much well-rounded scientific “factual” knowledge about your drug, you “hire” the best which in this case would be immunologist since it is their field of medicine that deals exclusively with the mechanics and physiological functions of the human immune system. 

 

 

The most prominent of all immunologists to have worked on the Aldara/imiquimod pre-approval research program was Dr. Stephen Tyring, director of Departments of Microbiology & Immunology at The University of Texas at Galveston, Texas.  In fact, these departments are housed in the same building 3M’s Dr. Jim Lee told me had been built and donated to the UT System by 3M prior to implementing the Aldara clinical research program.  Conflict of interest? 

 

You make the call on this one.

 

 

The most prominent 3M figure in the program was Dr. Herbert Slade, director of 3M PHARMACEUTICALS, Division.  Through his deposition testimony we learned that he personally directed each of the “40 to 50” clinical trials which were mostly conducted by Dr. Tyring.  The following is an abstract of his resume provided in his deposition testimony.

 

Slade Testimony:

 

I’m the head of medical affairs globally, and so I am particularly responsible for all clinical development, all post-marketing surveillance, all medical issues; and a board certified clinical immunologist with 12 years in the pharmaceutical (industry) and focused on immunologic types of treatments.

 

So when time allows, I get more involved in particular protocols and issues of science.

 

 

Wow!  This guy is definitely a heavy-weight.  Which means that he in no way shape or form could ever hide behind a statement or self-imposed smoke screen declaring himself unqualified, or that he is not the best person to ask about and receive answers to particular questions concerning the drug Aldara / imiquimod.  In fact, Dr. Slade “IS” the final word, on the subject of Aldara as he clearly demonstrates through his testimony.

 

So, we have to assume that between these two guys, Dr. Tyring and Dr. Slade, they know the answers to the hard questions about Aldara and 3M internal affairs surrounding the “total” Aldara program. 

 

During his Federal Court testimony, when Slade says he doesn’t know or can’t remember, or he is not qualified to answer a particular question having to do with Aldara, imiquimod, or 3M operations, I can not believe he is being truthful.  He is the number one “front man” for the entire 3M Pharmaceuticals Division of 3M, world wide, so he is charged with having the answers to any and all questions having anything to do with 3M Pharmaceuticals or believe me 3M would remove him from his position.

 

It's interesting that during his testimony, Dr. Slade seems to have all the answers to any "positive" questions about Aldara yet just doesn't seem to be the person with any knowledge of answers to any "negative" questions" 3M learned about the drug during HIS DIRECTORSHIP OF RESEARCH on the drug.  Interesting observation!